Harrow to Launch FDA-Approved IHEEZO™ at the 2023 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
Harrow (NASDAQ: HROW), a leading U.S. eyecare pharmaceutical
company, today announced the launch of FDA-approved IHEEZO™ at the
2023 American Society of Cataract and Refractive Surgery (ASCRS)
annual meeting being held May 5‑8, 2023, in San Diego, California.
The Harrow commercial team will be available to discuss IHEEZO and
the entire Harrow portfolio of ophthalmic pharmaceutical products
at ASCRS booth #2237.
IHEEZO is a sterile, single-patient-use, physician-administered,
ophthalmic gel preparation, containing no preservatives, that is
safe and effective for ocular surface anesthesia. IHEEZO, which has
been issued a J‑Code (J2403) and transitional pass-through
reimbursement status by the Centers for Medicare & Medicaid
Services (CMS), represents the first approved use in the U.S.
ophthalmic market of chloroprocaine hydrochloride and the first
branded ocular anesthetic approved for the U.S. ophthalmic market
in nearly 14 years.
IHEEZO Launch Events
- Dr. Richard L. Lindstrom will be making a presentation titled,
Prospective, Randomized Comparison of Chloroprocaine 3% Gel and
Tetracaine 0.5% Solution for Cataract Surgery Anesthesia. The
presentation is scheduled during the Medications (Preoperative,
Postoperative, Intraoperative) session on Sunday, May 7th,
beginning at 3:40 p.m. PT in the SDCC, Upper Level, Room 5A.
- Dr. William Wiley will speak about his experience using IHEEZO
during a booth talk scheduled to begin at 1:30 p.m. PT at Harrow’s
booth #2237 on Saturday, May 6th.
- Harrow will host the “Harrow Brings Nashville to San Diego”
IHEEZO Launch Event at the Hard Rock Hotel in downtown San Diego
from 5:30-7:30 p.m. on Saturday, May 6th. To attend the event and
learn more about IHEEZO, please register by clicking here.
All educational content of the ASCRS Annual Meeting is planned
by its program committee. ASCRS does not endorse, promote, approve,
or recommend using any products, devices, or services.
Harrow (Nasdaq: HROW) is a leading U.S. eyecare pharmaceutical
company engaged in the discovery, development, and
commercialization of innovative ophthalmic prescription therapies
that are accessible and affordable. Harrow owns U.S. commercial
rights to ten FDA-approved ophthalmic pharmaceutical products.
Harrow also owns and operates ImprimisRx, the leading U.S.
ophthalmic-focused pharmaceutical compounding business, which also
serves as a mail-order pharmacy licensed to ship prescription
medications in all 50 states. Harrow has non-controlling equity
positions in Surface Ophthalmics, Inc. and Melt Pharmaceuticals,
Inc., companies that began as subsidiaries of Harrow. Harrow also
owns royalty rights in four late-stage drug candidates being
developed by Surface and Melt.
This press release contains “forward-looking statements” within
the meaning of the U.S. Private Securities Litigation Reform Act of
1995. Any statements in this release that are not historical facts
may be considered such “forward-looking statements.”
Forward-looking statements are based on management's current
expectations and are subject to risks and uncertainties which may
cause results to differ materially and adversely from the
statements contained herein. Some of the potential risks and
uncertainties that could cause actual results to differ from those
predicted include the continued impact of the COVID-19 pandemic and
any future health epidemics on our financial condition, liquidity
and results of operations; our ability to make commercially
available our FDA‑approved products and compounded formulations and
technologies in a timely manner or at all; market acceptance of the
Company’s products and challenges related to the marketing of the
Company’s products; risks related to our pharmacy operations; our
ability to enter into other strategic alliances, including
arrangements with pharmacies, physicians and healthcare
organizations for the development and distribution of our products;
our ability to obtain intellectual property protection for our
assets; our ability to accurately estimate our expenses and cash
burn, and raise additional funds when necessary; risks related to
research and development activities; the projected size of the
potential market for our technologies and products; unexpected new
data, safety and technical issues; regulatory and market
developments impacting compounding pharmacies, outsourcing
facilities and the pharmaceutical industry; competition; and market
conditions. These and additional risks and uncertainties are more
fully described in Harrow’s filings with the Securities and
Exchange Commission, including its Annual Report on Form 10-K and
its Quarterly Reports on Form 10-Q. Such documents may be read free
of charge on the SEC's website at sec.gov. Undue reliance should
not be placed on forward-looking statements, which speak only as of
the date they are made. Except as required by law, Harrow
undertakes no obligation to update any forward-looking statements
to reflect new information, events, or circumstances after the date
they are made, or to reflect the occurrence of unanticipated
ImprimisRx specializes in customizing medications to meet unique
patient and practitioner needs. No compounded medication is
reviewed by the FDA for safety or efficacy. ImprimisRx does not
compound copies of commercially available products.
version on businesswire.com: https://www.businesswire.com/news/home/20230504005342/en/
Investors Jamie Webb
Director of Communications and Investor Relations
firstname.lastname@example.org 615-733-4737 Media Deb Holliday Holliday Communications,
Inc. email@example.com 412-877-4519
Harrow Health (NASDAQ:HROW)
Historical Stock Chart
From Aug 2023 to Sep 2023
Harrow Health (NASDAQ:HROW)
Historical Stock Chart
From Sep 2022 to Sep 2023